tirzepatide and epilepsy Could GLP-1 Drugs Lower Risk in People with Diabetes? Tirzepatide and Brain Disease; Lamotrigine

The median values of BMI (36.9 kg/m 2 ) and WC (120 cm) suggested a high prevalence of central obesity among the study participants, who also exhibited clinically relevant insulin resistance (median HOMA-IR value 5.5

What other newer agents are on the horizon for treatment of obesity

Research examined in the 2016 review suggests that these SCFAs can stimulate GLP-1 release by binding to L-cell receptors

During your initial consultation, we will conduct an evaluation, check vital signs, perform lab tests, review your diet and exercise routines, and set achievable weight loss objectives

Mounjaro targets both GIP and GLP-1 receptors (dual action), while Wegovy targets only GLP-1 (single action)

Stephanie shares her perspective on the growing popularity of weight loss supplements, prescription medications, and the importance of behaviour change for sustainable results